Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

E. J.T. Verweij; Abera Tura; Tadesse Gure; Jeremia Pyuza; Bariki Mchome; Kondwani Kawaza; Peter Moons; Derek de Winter; Renske van't Oever; Steven Spitalnik; C. Ellen van der Schoot; Thomas van den Akker

doi:10.1016/s0140-6736(23)01888-3

Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

E. J.T. Verweij
, Abera Tura
, Tadesse Gure
, Jeremia Pyuza
, Bariki Mchome
, Kondwani Kawaza
, Peter Moons
, Derek de Winter
, Renske van't Oever
, Steven Spitalnik
, C. Ellen van der Schoot
, Thomas van den Akker

Research output: Contribution to journal › Letter › peer-review

10 Citations (Scopus)

Original language	English
Pages (from-to)	806-807
Number of pages	2
Journal	The Lancet
Volume	403
Issue number	10429
DOIs	https://doi.org/10.1016/s0140-6736(23)01888-3
Publication status	Published - 2 Mar 2024
Externally published	Yes

Access to Document

10.1016/s0140-6736(23)01888-3

Cite this

@article{61e117e5587d4623962a56773e1cc92a,

title = "Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy",

author = "Verweij, \{E. J.T.\} and Abera Tura and Tadesse Gure and Jeremia Pyuza and Bariki Mchome and Kondwani Kawaza and Peter Moons and \{de Winter\}, Derek and \{van't Oever\}, Renske and Steven Spitalnik and \{van der Schoot\}, \{C. Ellen\} and \{van den Akker\}, Thomas",

year = "2024",

month = mar,

day = "2",

doi = "10.1016/s0140-6736(23)01888-3",

language = "English",

volume = "403",

pages = "806--807",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10429",

}

TY - JOUR

T1 - Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

AU - Verweij, E. J.T.

AU - Tura, Abera

AU - Gure, Tadesse

AU - Pyuza, Jeremia

AU - Mchome, Bariki

AU - Kawaza, Kondwani

AU - Moons, Peter

AU - de Winter, Derek

AU - van't Oever, Renske

AU - Spitalnik, Steven

AU - van der Schoot, C. Ellen

AU - van den Akker, Thomas

PY - 2024/3/2

Y1 - 2024/3/2

U2 - 10.1016/s0140-6736(23)01888-3

DO - 10.1016/s0140-6736(23)01888-3

M3 - Letter

SN - 0140-6736

VL - 403

SP - 806

EP - 807

JO - The Lancet

JF - The Lancet

IS - 10429

ER -